O	0	10	Protective
O	11	18	effects
O	19	21	of
B-intervention	22	31	nebivolol
O	32	39	against
B-condition	40	53	anthracycline
I-condition	53	54	-
I-condition	54	61	induced
I-condition	62	76	cardiomyopathy
O	76	77	:
O	78	79	a
O	80	90	randomized
O	91	98	control
O	99	104	study
O	104	105	.

O	106	108	We
O	109	114	aimed
O	115	117	to
O	118	126	evaluate
O	127	130	the
O	131	137	effect
O	138	140	of
O	141	153	prophylactic
O	154	163	nebivolol
O	164	167	use
O	168	170	on
O	171	181	prevention
O	182	184	of
O	185	197	antracycline
O	197	198	-
O	198	205	induced
O	206	220	cardiotoxicity
O	221	223	in
O	224	230	breast
O	231	237	cancer
O	238	246	patients
O	246	247	.

O	248	250	In
O	251	255	this
O	256	261	small
O	261	262	,
O	263	274	prospective
O	274	275	,
O	276	282	double
O	282	283	-
O	283	288	blind
O	289	294	study
O	294	295	,
O	296	298	we
O	299	307	randomly
O	308	316	assigned
B-total-participants	317	319	45
O	320	331	consecutive
O	332	340	patients
O	341	345	with
O	346	352	breast
O	353	359	cancer
O	360	363	and
O	364	371	planned
O	372	385	chemotheraphy
O	386	388	to
O	389	396	receive
O	397	406	nebivolol
O	407	410	5mg
O	411	416	daily
O	417	418	(
O	418	419	n
O	419	420	=
B-intervention-participants	420	422	27
O	422	423	)
O	424	426	or
B-control	427	434	placebo
O	435	436	(
O	436	437	n
O	437	438	=
B-control-participants	438	440	18
O	440	441	)
O	441	442	.

O	443	460	Echocardiographic
O	461	473	measurements
O	474	477	and
O	478	479	N
O	479	480	-
O	480	488	terminal
O	489	492	pro
O	492	493	-
O	493	498	brain
O	499	510	natriuretic
O	511	518	peptide
O	519	520	(
O	520	522	NT
O	522	523	-
O	523	526	pro
O	526	527	-
O	527	530	BNP
O	530	531	)
O	532	538	levels
O	539	543	were
O	544	552	obtained
O	553	555	at
O	556	564	baseline
O	565	568	and
O	569	571	at
O	572	573	6
O	573	574	-
O	574	579	month
O	580	582	of
O	583	595	chemotherapy
O	595	596	.

O	597	601	Both
O	602	609	studied
O	610	616	groups
O	617	620	had
O	621	631	comparable
B-outcome	632	649	echocardiographic
I-outcome	650	659	variables
O	660	663	and
O	664	666	NT
O	666	667	-
O	667	670	pro
O	670	671	-
O	671	674	BNP
O	675	681	levels
O	682	684	at
O	685	693	baseline
O	693	694	.

B-outcome	695	697	At
I-outcome	698	699	6
I-outcome	699	700	-
I-outcome	700	705	month
O	705	706	,
O	707	710	the
B-outcome	711	715	left
I-outcome	716	727	ventricular
I-outcome	728	729	(
I-outcome	729	731	LV
I-outcome	731	732	)
I-outcome	733	736	end
I-outcome	736	737	-
I-outcome	737	745	systolic
O	746	749	and
B-outcome	750	753	end
I-outcome	753	754	-
I-outcome	754	763	diastolic
I-outcome	764	773	diameters
O	774	783	increased
O	784	786	in
O	787	790	the
O	791	798	placebo
O	799	804	group
O	805	806	(
B-outcome	806	811	LVESD
O	811	812	:
B-cv-cont-mean	813	815	29
I-cv-cont-mean	815	816	.
I-cv-cont-mean	816	817	7
O	818	819	±
B-cv-cont-sd	820	821	3
I-cv-cont-sd	821	822	.
I-cv-cont-sd	822	823	4
O	824	826	to
B-cv-cont-mean	827	829	33
I-cv-cont-mean	829	830	.
I-cv-cont-mean	830	831	4
O	832	833	±
B-cv-cont-sd	834	835	4
I-cv-cont-sd	835	836	.
I-cv-cont-sd	836	839	5mm
O	839	840	;
B-outcome	841	846	LVEDD
O	846	847	:
B-cv-cont-mean	848	850	47
I-cv-cont-mean	850	851	.
I-cv-cont-mean	851	852	2
O	853	854	±
B-cv-cont-sd	855	856	3
I-cv-cont-sd	856	857	.
I-cv-cont-sd	857	858	8
O	859	861	to
B-cv-cont-mean	862	864	52
I-cv-cont-mean	864	865	.
I-cv-cont-mean	865	866	0
O	867	868	±
B-cv-cont-sd	869	870	4
I-cv-cont-sd	870	871	.
I-cv-cont-sd	871	874	6mm
O	874	875	,
O	876	877	p
O	877	878	=
O	878	879	0
O	879	880	.
O	880	882	01
O	883	886	for
O	887	891	both
O	891	892	)
O	893	896	but
O	897	905	remained
O	906	915	unchanged
O	916	918	in
O	919	922	the
O	923	932	nebivolol
O	933	938	group
O	939	940	(
B-outcome	940	945	LVESD
O	945	946	:
B-iv-cont-mean	947	949	30
I-iv-cont-mean	949	950	.
I-iv-cont-mean	950	951	4
O	952	953	±
B-iv-cont-sd	954	955	3
I-iv-cont-sd	955	956	.
I-iv-cont-sd	956	957	5
O	958	960	to
B-iv-cont-mean	961	963	31
I-iv-cont-mean	963	964	.
I-iv-cont-mean	964	965	0
O	966	967	±
B-iv-cont-sd	968	969	3
I-iv-cont-sd	969	970	.
I-iv-cont-sd	970	973	6mm
O	973	974	,
O	975	976	p
O	976	977	=
O	977	978	0
O	978	979	.
O	979	981	20
O	981	982	;
B-outcome	983	988	LVEDD
O	988	989	:
B-iv-cont-mean	990	992	47
I-iv-cont-mean	992	993	.
I-iv-cont-mean	993	994	0
O	995	996	±
B-iv-cont-sd	997	998	4
I-iv-cont-sd	998	999	.
I-iv-cont-sd	999	1000	4
O	1001	1003	to
B-iv-cont-mean	1004	1006	47
I-iv-cont-mean	1006	1007	.
I-iv-cont-mean	1007	1008	1
O	1009	1010	±
B-iv-cont-sd	1011	1012	4
I-iv-cont-sd	1012	1013	.
I-iv-cont-sd	1013	1016	0mm
O	1016	1017	,
O	1018	1019	p
O	1019	1020	=
O	1020	1021	0
O	1021	1022	.
O	1022	1024	93
O	1024	1025	)
O	1025	1026	.

O	1027	1030	The
O	1031	1038	placebo
O	1039	1044	group
O	1045	1049	also
O	1050	1053	had
O	1054	1059	lower
B-outcome	1060	1064	LVEF
O	1065	1069	than
O	1070	1073	the
O	1074	1083	nebivolol
O	1084	1089	group
O	1090	1091	(
B-cv-cont-mean	1091	1093	57
I-cv-cont-mean	1093	1094	.
I-cv-cont-mean	1094	1095	5
O	1096	1097	±
B-cv-cont-sd	1098	1099	5
I-cv-cont-sd	1099	1100	.
I-cv-cont-sd	1100	1101	6
I-cv-cont-sd	1101	1102	%
O	1103	1105	vs
O	1105	1106	.
B-iv-cont-mean	1107	1109	63
I-iv-cont-mean	1109	1110	.
I-iv-cont-mean	1110	1111	8
O	1112	1113	±
B-iv-cont-sd	1114	1115	3
I-iv-cont-sd	1115	1116	.
I-iv-cont-sd	1116	1117	9
I-iv-cont-sd	1117	1118	%
O	1118	1119	,
O	1120	1121	p
O	1121	1122	=
O	1122	1123	0
O	1123	1124	.
O	1124	1126	01
O	1126	1127	)
B-outcome	1128	1130	at
I-outcome	1131	1132	6
I-outcome	1132	1133	-
I-outcome	1133	1138	month
O	1138	1139	.

B-outcome	1140	1142	NT
I-outcome	1142	1143	-
I-outcome	1143	1146	pro
I-outcome	1146	1147	-
I-outcome	1147	1150	BNP
I-outcome	1151	1156	level
O	1157	1165	remained
O	1166	1172	static
O	1173	1175	in
O	1176	1179	the
O	1180	1189	nebivolol
O	1190	1195	group
O	1196	1197	(
B-iv-cont-mean	1197	1200	147
O	1201	1202	±
B-iv-cont-sd	1203	1205	57
O	1206	1208	to
B-iv-cont-mean	1209	1212	152
O	1213	1214	±
B-iv-cont-sd	1215	1217	69
I-iv-cont-sd	1218	1222	pmol
I-iv-cont-sd	1222	1223	/
I-iv-cont-sd	1223	1224	l
O	1224	1225	,
O	1226	1227	p
O	1227	1228	=
O	1228	1229	0
O	1229	1230	.
O	1230	1232	77
O	1232	1233	)
O	1234	1239	while
O	1240	1242	it
O	1243	1252	increased
O	1253	1255	in
O	1256	1259	the
O	1260	1267	placebo
O	1268	1273	group
O	1274	1275	(
B-cv-cont-mean	1275	1278	144
O	1279	1280	±
B-cv-cont-sd	1281	1283	66
O	1284	1286	to
B-cv-cont-mean	1287	1290	204
O	1291	1292	±
B-cv-cont-sd	1293	1295	73
I-cv-cont-sd	1296	1300	pmol
I-cv-cont-sd	1300	1301	/
I-cv-cont-sd	1301	1302	l
O	1302	1303	,
O	1304	1305	p
O	1305	1306	=
O	1306	1307	0
O	1307	1308	.
O	1308	1310	01
O	1310	1311	)
O	1311	1312	.

O	1313	1325	Prophylactic
O	1326	1329	use
O	1330	1332	of
O	1333	1342	nebivolol
O	1343	1352	treatment
O	1353	1356	may
O	1357	1364	protect
O	1365	1368	the
O	1369	1379	myocardium
O	1380	1387	against
O	1388	1400	antracycline
O	1400	1401	-
O	1401	1408	induced
O	1409	1423	cardiotoxicity
O	1424	1426	in
O	1427	1433	breast
O	1434	1440	cancer
O	1441	1449	patients
O	1449	1450	.
